Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma

Table 1

Clinical characteristics of the 55 patients with multiple myeloma.

Characteristics	Number (%) or median (range)
Number of patients	55
Age	61 (38–78)
Gender (male : female)	36 : 19 (65 : 35)
Durie-Salmon stage (I : II : III)	5 : 10 : 40 (9 : 18 : 73)
ISS stage (I : II : III)	22 : 18 : 15 (40 : 33 : 27)
Calcium (mg/dL)	9.1 (7.2–13.0)
Creatinine (mg/dL)	1.2 (0.7–3.9)
Albumin (mg/dL)	4.0 (2.3–4.9)
β2-Microglobulin (mg/dL)	3.8 (1.6–19.0)
Hemoglobin (g/dL)	10.3 (6.0–16.2)
Lactate dehydrogenase (U/L)	167 (79–1832)
C-reactive protein (mg/dL)	0.27 (0–10.01)
IgG : IgA : IgM : IgD : IgE : light* : biclonal	33 : 11 : 0 : 0 : 0 : 9 : 2 (60 : 20 : 0 : 0 : 0 : 16 : 4)
Kappa : Lambda (electrophoresis)	23 : 22^† (51 : 49)
Plasma cell type
Mature	39 (71)
Immature	9 (16)
Plasmablastic	2 (4)
Pleomorphic	5 (9)
Infiltration pattern
Interstitial	16 (29)
Focal	3 (5)
Diffuse	36 (66)
Frequency of CD138-positive cells on biopsy^‡	80 (10–100)
Cytogenetics (FISH)
1q gain^†	21/47 (45)
13q deletion^†	19/47 (40)
t(4;14)^†	8/48 (17)
17p deletion^†	2/41 (5)

ISS: international staging system; FISH: fluorescent in situ hybridization; *light chain type; ^†absent values due to tests not done; the percentages are calculated based on the number of tests completed; ^‡immunohistochemical stain on bone marrow biopsy.